Nuclear Medicine Imaging for Neurodegenerative and Metabolic Disease
This community focuses on the use of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) to diagnose and monitor conditions such as Alzheimer’s disease, Parkinson’s disease, and bone metabolism disorders.
The work centers on the synthesis and application of radiotracers, particularly 18F-fluorodeoxyglucose (FDG), for brain imaging and bone scintigraphy. Recurring themes include the evaluation of cognitive impairment, dopamine transporter imaging for movement disorders, and the diagnosis of infections such as infective endocarditis. The literature frequently addresses clinical diagnostic criteria, case reports, and the integration of molecular imaging with magnetic resonance imaging (MRI). Specific applications include assessing amyloid and tau pathology in neurodegeneration and evaluating bone metabolic activity in the spine.
The largest share of the community's output is found in Technetium research, accounting for 22.8% of that element's tracked literature, with 4,815 papers in this group. Rhenium research follows with a 10.2% share, representing 2,201 papers.
The community comprises 29,595 papers, published primarily in Clinical Nuclear Medicine, the European Journal of Nuclear Medicine and Molecular Imaging, and Nuclear Medicine Communications.
Recent work includes studies on the diagnostic landscape of Alzheimer’s disease, regional tau PET patterns for predicting cognitive decline, and the evaluation of bone metabolic activity using 18F-sodium fluoride PET.